Not yet recruitingNCT07337967Updated Jan 13, 2026

Reticulocyte Parameters as Early Indicators of Bone Marrow Erythropoietic Activity in Chronic B Lymphoproliferative Neoplasms

An observational study in B Chronic Lymphocytic Leukemia, sponsored by Huda Ahmed Abdelsabour Abdelwahab. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Huda Ahmed Abdelsabour Abdelwahab · Observational

Study type: Observational
Model: Other
Time perspective: Cross-sectional
Enrollment: 120
Ages: 18 Years and older
Sex: All

Study summary

Reticulocyte parameters as early indicators of bone marrow erythropoietic activity in chronic B lymphoproliferative neoplasms

Conditions studied

B Chronic Lymphocytic Leukemia

Browse trials for

Leukemia, B-Cell 190

In context

Leukemia, B-Cell

190 studies on the registry are indexed under Leukemia, B-Cell; 52 are open to participants now.

This study's planned enrollment of 120 is close to the median of 120 across 22 observational studies indexed under Leukemia, B-Cell.

Browse Leukemia, B-Cell studies →

Lead sponsor

This is the only study on the registry with Huda Ahmed Abdelsabour Abdelwahab as lead sponsor.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years and older
Sexes eligible: All
Accepts healthy volunteers: Yes
Sampling method: Non-probability sample

Study population

Newly diagnosed adult patients with Chronic B LymphoPoliferative neoplasm according to WHO classification.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Newly diagnosed adult patients with Chronic B LymphoPoliferative neoplasm according to WHO classification.

Exclusion criteria

Exclusion Criteria:

1) Patients received chemotherapy.

Patients with Active bleeding
Patients with recent blood transfusion (less than 2 weeks).
Patients on haematinics or vitamin B 12 therapy

Study design

Observational model: Other
Time perspective: Cross-sectional
Enrollment: 120 participants (estimated)
Target follow-up: 1 Year
Patient registry: Yes

What researchers measure

Primary outcomes

Reticulocyte count
Absolute peripheral blood reticulocyte count measured in patients with chronic B-cell lymphoproliferative disorders (CLPDs). Unit of Measure: ×10⁹/L
Time frame: 1 year
Reticulocyte percentage
Percentage of reticulocytes among total red blood cells in peripheral blood of patients with CLPDs. Unit of Measure: %
Time frame: 1 year
Immature reticulocyte fraction (IRF)
Proportion of immature reticulocytes in peripheral blood measured in patients with CLPDs. Unit of Measure: %
Time frame: 1 year

Study locations

No study locations are listed for this record.

Timeline

Tracking since Sep 25, 2026

ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2026; primary completion for Feb 2027, 13 months later.

How these figures are worked out, and which studies are left out of them.

Registered: Dec 13, 2025
First posted: Jan 13, 2026
StartEst.: Jan 1, 2026
Primary completionEst.: Feb 1, 2027
CompletionEst.: Sep 1, 2027
Last update: Jan 13, 2026

What these dates mean

Start.: When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.: When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.: When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.: Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.

No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT07337967
Lead sponsor: Huda Ahmed Abdelsabour Abdelwahab
Responsible party: Huda Ahmed Abdelsabour Abdelwahab (Resident doctor, Assiut University) — Sponsor-investigator
First posted: Jan 13, 2026
Start date: Jan 1, 2026 (estimated)
Primary completion: Feb 1, 2027 (estimated)
Completion: Sep 1, 2027 (estimated)
Last update: Jan 13, 2026

Oversight

FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Leukemia, B-Cell →

Start the discussion